Daily coverage of equity markets, sectors, and major indices.
In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.
25,496 total articles
Enhabit Inc. agreed to be acquired by private equity firm Kinderhook Industries in an all-cash transaction valued at roughly $1.1 billion. The deal, unanimously approved by Enhabit’s board, will pay stockholders $13.80 per share and is expected to close in the second quarter of 2026 subject to customary approvals. Following the announcement, Enhabi…
U.S. equity benchmarks closed higher on Friday after the Supreme Court curtailed much of President Trump's tariff program, a move that could ease cost pressures for businesses. The S&P 500, Nasdaq and Dow all posted gains for the day and week, while attention shifts to Nvidia's upcoming earnings and a docket of economic reports due in the coming da…
Psyence Biomedical Ltd. (NASDAQ:PBM) said it will acquire 2,900 shares of Psyence Labs Ltd. through a share-for-share exchange after Psyence Labs exercised a previously disclosed put option. The Labs shares are valued at $5 million using a per-share fair market valuation of $1,724. In return, Psyence Biomedical will issue 1,146,159 common shares to…
MoonLake Immunotherapeutics saw its stock climb in premarket trading after disclosing topline results from the Phase 2 S-OLARIS study of sonelokimab in axial spondyloarthritis (axSpA). The data showed high rates of clinical response at Week 12, corroborated by PET and MRI imaging, while the safety profile remained consistent with earlier studies. T…
Gossamer Bio's stock plunged 80% on Monday after its inhaled investigational therapy seralutinib did not meet the primary endpoint in the Phase 3 PROSERA study for pulmonary arterial hypertension (PAH). The trial showed a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of 13.3 meters at Week 24 with a p-value of 0.0320, missing the …
President Trump announced an across-the-board 15% tariff under Section 122 following a Supreme Court decision that invalidated his prior use of emergency powers to impose tailored levies. Wolfe Research analysts Tobin Marcus and Chutong Zhu reviewed the major open questions this development leaves in its wake, including how much the 15% rate narrow…
Armata Pharmaceuticals saw premarket gains after the U.S. Food and Drug Administration awarded Qualified Infectious Disease Product (QIDP) designation to AP-SA02, its multi-phage intravenous candidate for complicated Staphylococcus aureus bacteremia. The designation confers regulatory incentives, including five years of market exclusivity and eligi…
Rothschild Redburn has downgraded Airbus Group SE to Neutral and reduced its price target to €200 from €230, citing operational setbacks on the A320neo and A350 programmes that outweigh robust market demand. The brokerage highlights quality issues, engine supply shortages and broader supply-chain limits that could delay production ramp-ups and weig…
Eli Lilly premarket shares rose after Novo Nordisk reported its experimental obesity drug CagriSema did not meet the trial's primary endpoint of non-inferiority to Eli Lilly's Tirzepatide. The trial showed a 23% weight reduction for CagriSema versus 25.5% for Tirzepatide over 84 weeks. Novo Nordisk will test a higher dose in the second half of 2026…
Vertical Aerospace (NYSE: EVTL) shares fell 2.7% in premarket trading after Raymond James downgraded the stock from Market Perform to Underperform. Analyst Savanthi Syth pointed to concerns about the company’s financial runway, competitive pressure from rivals, and potential talent losses, while noting the company is seeking an industrial partner t…
Acadia Pharmaceuticals shares rose 1.9% in premarket trading after Mizuho analyst Uy Ear upgraded the stock from Neutral to Outperform and lifted the price target to $35.00 from $29.00. The upgrade reflects a view that remlifanserin (ACP-204), Acadia’s Phase 2 candidate in the RADIANT trial for Alzheimer’s disease psychosis, is undervalued, and tha…
Investor Ed Garden's firm has accumulated a meaningful stake in Fortune Brands Innovations (FBIN) and is pressing for leadership and board changes, including efforts to replace the incoming CEO. The move follows a recent CEO departure, weak quarterly results and a rapid announcement of a successor. Fortune Brands' shares moved higher in premarket t…
Bank of America analysts say recent market strength has provided some relief for trend-following funds, but positioning remains stretched and the risk of a commodity trading advisor (CTA) unwind is still elevated. Systematic strategies could sell materially in a down market, with estimates as high as $132 billion across models and up to $95 billion…
Hamborner REIT AG has revised its portfolio composition to materially reduce office weighting and provided guidance for the 2026 financial year, forecasting funds from operations (FFO) between €38.0 million and €42.0 million and expected rental income of €87.5 million to €89.5 million. The firm attributes a projected decline in rental receipts to p…
Atomera Incorporated (NASDAQ:ATOM) saw its stock fall 15% on Monday after announcing a $25 million registered direct offering to institutional investors. The company agreed to sell 5,000,000 shares at $5.00 per share under a securities purchase agreement, with the transaction expected to close on or about February 24, 2026, subject to customary clo…
Gilead Sciences agreed to acquire Arcellx for $115 in cash per share plus a $5 contingent value right, an agreement that values Arcellx at about $7.8 billion. The transaction, approved by both boards and expected to close in Q2 2026 subject to customary conditions, consolidates Gilead's control of anito-cel, an investigational BCMA-directed CAR T t…
Citi told clients that fourth-quarter results and steady consensus estimates underpin its optimistic outlook for 2026. Analyst Scott Chronert reiterated that the firm "maintains a constructive fundamental outlook for 2026," citing positive Q4 2025 earnings trends, accelerating sales across market caps and an above-consensus S&P 500 earnings project…
Shares of Shutterstock and Getty Images rose after the U.S. Department of Justice concluded its antitrust review and the Hart-Scott-Rodino waiting period expired without conditions, marking a key regulatory milestone for the proposed merger of equals. The companies say the deal should unlock synergies, but a Phase 2 review by the U.K. Competition a…
Two real estate investment trusts, Innovative Industrial Properties (IIPR) and Arbor Realty Trust (ABR), are attracting attention for their current yields north of 16% and multi-year payout characteristics heading into 2026. WarrenAI highlights IIPR for its consistent dividend growth and a nine-year payment streak, while ABR is noted for its high c…
UBS reduced its recommendation on Swiss regional bank Valiant Holding AG from buy to neutral while nudging its 12-month price target up to CHF168 from CHF155. The brokerage argued that the stock's rally and announced capital returns have largely captured the upside potential, leaving limited expected outperformance versus UBS's market return assump…
Warner Bros. Discovery shares gained on Monday after reports indicated that Paramount Skydance, led by David Ellison, is poised to submit an enhanced takeover proposal of $32 per share. The company faces a deadline to file a best and final offer within a weeklong window granted by Warner Bros. Discovery's board, a period that ends at 11:59 p.m. ET …
CenterPoint Energy shares fell 2.7% to $41.85 in premarket trading after the company announced a private placement of $550 million in convertible bonds due May 2029. The Houston-based utility said net proceeds will be used for general corporate purposes, including repaying commercial paper and other debt. The move follows a record high close of $43…
Gilead Sciences agreed to acquire Arcellx for up to $7.8 billion in cash, paying $115 per share - a 79% premium to Arcellx's last close - to strengthen its cancer-treatment offerings. The deal links Gilead, through its Kite Pharma unit, to the development of anito-cel, an investigational CAR-T therapy for multiple myeloma that is under FDA review w…
Deutsche Bank raised price targets across several Spanish banks and upgraded ratings for Bankinter, Banco Sabadell and CaixaBank after analysts observed stronger-than-expected net interest income resilience in 2025, diversified fee income and tighter cost control. The bank expects net interest income to resume growth in 2026 and projects returns on…
Celsius Holdings shares climbed after management disclosed larger-than-expected shelf space increases for both Alani Nu and the Celsius brand at a recent investor conference. TD Cowen reiterated a Buy rating and highlighted the quantified distribution gains, while projecting above-consensus sales and EBITDA for coming years.
